Natera (NTRA) Q3 FY2026 Earnings Call: Q&A Summary

Q: Daniel Brennan from TD Cowen asked about top priorities for CEO Solomon Moshkevich and how his strategy might differ from Steve Chapman.

A: Solomon Moshkevich answered that having worked at Natera for 15 years, there will be no radical changes, and the company will stick to the formula of providing great service, generating practice-changing data, and ensuring trusted test results.

Q: Daniel Brennan from TD Cowen asked about the levers behind the $6 billion opportunity and what assumptions were made for Signatera volume and ASP.

A: Solomon Moshkevich and Mike Brophy stated that hitting $6 billion by 2029 requires continued execution without heroic departures from historical performance, noting that ASPs could reach approximately $1,450, supported by MolDX coverage and clinical guideline expansion.

Q: Puneet Souda from Leerink Partners asked how to think about product growth and clinical trial cadence over the next 3 years within the $6 billion plan.

A: Solomon Moshkevich explained that many large pharma trials and early cancer screening contributions from the FIND trial will take years to read out, meaning growth to 2029 will be driven by existing businesses, core MRD expansion, ex-U.S. markets, and ASP increases.

Q: Puneet Souda from Leerink Partners asked for context regarding the timing and decision behind the management change.

A: Solomon Moshkevich stated that Steve Chapman and the Board agreed the time was right for a leadership transition from a position of strength.

Q: Subhalaxmi Nambi from Guggenheim asked Solomon Moshkevich about formative experiences informing his role as CEO.

A: Solomon Moshkevich responded that his leadership principles are rooted in integrity, honesty, accountability, and the shared experiences of scaling Natera from 40 to 6,500 employees.

Q: Puneet Souda from Leerink Partners asked if OpEx will step up again in 2027.

A: Mike Brophy stated that OpEx growth is expected to be in the 10% to 12% range for 2027, driven by investments in early cancer detection and MRD clinical trials.

Q: Daniel Markowitz from Evercore ISI asked how to balance future gross margin trajectory against newer dilutive products like Signatera genome and fetal focus.

A: Mike Brophy explained that the company aims for 70% plus gross margins long-term, and while new products may create short-term COGS pressure, they have 18 to 24-month projects in flight to reduce manufacturing costs.

Q: Casey Woodring from JPMorgan asked about the components contributing to the $6 billion target and details on pharma data investment in OpEx.

A: Mike Brophy and Solomon Moshkevich reiterated that the target relies on steady growth in women's health and organ health alongside Signatera expansion, and explained that pharma data investments include curation, abstraction, scientific staff, and software tools.

Q: Daniel Markowitz from Evercore ISI asked for an update on remaining MolDX submissions, aggregate potential revenue contributions, and TAM sizing.

A: Mike Brophy noted that there are 9 to 10 additional submissions currently in flight with MolDX, which will represent a large chunk of Signatera volume and drive upside to ASPs.

Q: Subhalaxmi Nambi from Guggenheim asked if industry consolidation in the prenatal market changes the competitive landscape for Natera's women's health business.

A: Solomon Moshkevich acknowledged market changes and dislocation, noting they have driven inbound interest and conversations while affirming Natera remains focused on customer satisfaction and innovation.

Q: Tycho Peterson from Jefferies asked about expectations for the upcoming commercial launch and reimbursement pathway in Japan.

A: Solomon Moshkevich stated that strong local clinical trial familiarity and guideline support suggest adoption could be at least as fast as in the U.S., with expected pricing accretive to U.S. ASPs.

Q: Tycho Peterson from Jefferies asked about the test mix between colorectal cancer, breast cancer, and newer indications, the impact of Signatera genome, and overall competitive dynamics.

A: Solomon Moshkevich and Alex Aleshin replied that colorectal and breast remain top contributors while newer indications like lung and bladder grow, that Signatera genome adoption is manageable despite short-term costs, and that competition is welcomed and handled through continuous clinical validation and customer support.